What is apixaban (apixaban)?
Apixaban is an oral anticoagulant and direct inhibitor of Factor Xa which is used to decrease the risk of venous thromboses, systemic embolization and stroke in patients with atrial fibrillation, and lower the risk of deep vein thrombosis and pulmonary embolus after knee or hip replacement surgery.
What is the difference between apixaban and dalteparin?
Apixaban was given orally at a dose of 10 mg twice daily for the first 7 days and 5 mg twice daily thereafter. Dalteparin was given subcutaneously at a dose of 200 IU per kilogram of body weight once daily for the first month, after which the dose was reduced to 150 IU per kilogram daily. The maximum daily dose allowed for dalteparin was 18,000 IU.
What are the treatment options for active bleeding on apixaban?
In the absence of published data, patients actively bleeding on apixaban should receive standard supportive treatment. Quantitative assays of apixaban level such as chromogenic anti-Xa assays are becoming available but their utility is unproven in this setting.
How long does apixaban take to work?
Apixaban is absorbed in the stomach and small intestine. For doses up to 10 mg, the absolute bioavailability is about 50%. For oral administration, absorption is not affected by the presence of food, and it takes about 3-4 hours to achieve maximum plasma concentrations.
Apixaban, an orally active, selective, direct factor Xa inhibitor, has been shown to reduce the incidence of venous thromboembolism in patients undergoing orthopedic surgery and to prevent thromboembolic events in patients with atrial fibrillation who are not candidates for oral vitamin K antagonist therapy.
How many mg of apixaban do you give a day?
Patients were randomly assigned, in a 1:1 ratio, to receive apixaban, at a dose of 5 mg twice daily, or matching placebo. Patients with an estimated creatinine clearance of less than 40 ml per minute at the time of randomization were randomly assigned to receive apixaban at a dose of 2.5 mg twice daily or matching placebo.
Does apixaban (apixaban) reduce the risk of recurrent ischemic events?
Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome.
Why was the apixaban trial terminated prematurely?
The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events.